Abstract
Pandemic, epidemic and endemic infectious diseases are united by a common problem: how do we rapidly and cost-effectively identify potential pharmacological interventions to treat infections? Given the large number of emerging and neglected infectious diseases and the fact that they disproportionately afflict the poorest members of the global society, new ways of thinking are required to develop high productivity discovery systems that can be applied to a large number of pathogens. The growing availability of parasite genome data provides the basis for developing methods to prioritize, a priori potential drug targets and analyze the pharmacological landscape of an infectious disease. Thus the overall objective of infectious disease informatics is to enable the rapid generation of plausible, novel medical hypotheses of testable pharmacological experiments, by uncovering undiscovered relationships in the wealth of biomedical literature and databases that were collected for other purposes. In particular our goal is to identify potential drug targets present in a pathogen genome and prioritize which pharmacological experiments are most likely to discover drug-like lead compounds rapidly against a pathogen (i.e. which specific compounds and drug targets should be screened, in which assays and where they can be sourced). An integral part of the challenge is the development and integration of methods to predict druggability, essentiality, synthetic lethality and polypharmocology in pathogen genomes, while simultaneously integrating the inevitable issues of chemical tractability and the potential for acquired drug resistance from the start.
Keywords: Chemogenomics, target identification, druggable genome, Pandemic, epidemic and endemic infectious diseases, parasite genome data, priori potential, biomedical literature, pharmacological experiments, druggability, chemical tractability, acquired drug resistance, trypanosomiasis, lymphatic filariasis, onchocerciasis, schistosomiasis
Current Topics in Medicinal Chemistry
Title: Rapid Analysis of Pharmacology for Infectious Diseases
Volume: 11 Issue: 10
Author(s): Andrew L. Hopkins, G. Richard Bickerton, Ian M. Carruthers, Stephen K. Boyer, Harvey Rubin and John P. Overington
Affiliation:
Keywords: Chemogenomics, target identification, druggable genome, Pandemic, epidemic and endemic infectious diseases, parasite genome data, priori potential, biomedical literature, pharmacological experiments, druggability, chemical tractability, acquired drug resistance, trypanosomiasis, lymphatic filariasis, onchocerciasis, schistosomiasis
Abstract: Pandemic, epidemic and endemic infectious diseases are united by a common problem: how do we rapidly and cost-effectively identify potential pharmacological interventions to treat infections? Given the large number of emerging and neglected infectious diseases and the fact that they disproportionately afflict the poorest members of the global society, new ways of thinking are required to develop high productivity discovery systems that can be applied to a large number of pathogens. The growing availability of parasite genome data provides the basis for developing methods to prioritize, a priori potential drug targets and analyze the pharmacological landscape of an infectious disease. Thus the overall objective of infectious disease informatics is to enable the rapid generation of plausible, novel medical hypotheses of testable pharmacological experiments, by uncovering undiscovered relationships in the wealth of biomedical literature and databases that were collected for other purposes. In particular our goal is to identify potential drug targets present in a pathogen genome and prioritize which pharmacological experiments are most likely to discover drug-like lead compounds rapidly against a pathogen (i.e. which specific compounds and drug targets should be screened, in which assays and where they can be sourced). An integral part of the challenge is the development and integration of methods to predict druggability, essentiality, synthetic lethality and polypharmocology in pathogen genomes, while simultaneously integrating the inevitable issues of chemical tractability and the potential for acquired drug resistance from the start.
Export Options
About this article
Cite this article as:
L. Hopkins Andrew, Richard Bickerton G., M. Carruthers Ian, K. Boyer Stephen, Rubin Harvey and P. Overington John, Rapid Analysis of Pharmacology for Infectious Diseases, Current Topics in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/156802611795429130
DOI https://dx.doi.org/10.2174/156802611795429130 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Target-based Anti-angiogenic Therapy in Breast Cancer
Current Pharmaceutical Design Serine Protease Inhibitors and T Lymphocyte Immunity
Current Immunology Reviews (Discontinued) The Ayurvedic Bhasma: The Ancient Science of Nanomedicine
Recent Patents on Nanomedicine Novel Ligands: Fine Tuning the Transcriptional Activity of the Glucocorticoid Receptor
Current Pharmaceutical Design The Role of Reproductive Advantages in the Stable Prevalence of Schizophrenia
Current Psychiatry Reviews Impact of Immunogenetic Polymorphisms in Bone Marrow Failure Syndromes
Mini-Reviews in Medicinal Chemistry M2000, Foundation of a New Generation Among NSAIDs
Letters in Drug Design & Discovery Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery The Roles of Apoptosis in Wound Healing and Pulmonary Fibrosis
Drug Design Reviews - Online (Discontinued) EPA and DHA Differentially Affect In Vitro Inflammatory Cytokine Release by Peripheral Blood Mononuclear Cells from Alzheimer’s Patients
Current Alzheimer Research Pyridinylimidazole Based p38 MAP Kinase Inhibitors
Current Topics in Medicinal Chemistry Potential Use of Drugs that Target Neural-Immune Pathways in the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Preface (Hot Topic: Endocrine , Metabolic and Immunological Agents Executive Editors : Allan S . Wagman / Wayne L . Cody)
Current Pharmaceutical Design Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets